Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call
November 08 2021 - 4:01PM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that it will report third quarter 2021 financial
results on Monday, November 15, 2021. Management will host a
conference call and live audio webcast to discuss these results and
provide a business update at 8:30 a.m. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 7298039. To access a live webcast and subsequent
archived recording of the call, please visit “Events” in the
“Investors” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals,
Inc.
Kala is a commercial-stage biopharmaceutical company focused on
the discovery, development, and commercialization of innovative
therapies for diseases of the eye. Kala has applied its AMPPLIFY®
mucus-penetrating particle (MPP) Drug Delivery Technology to two
ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic
suspension) 0.25% for the short-term (up to two weeks) treatment of
signs and symptoms of dry eye disease and INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% for the treatment of
post-operative inflammation and pain following ocular surgery. The
Company also has a pipeline of pre-clinical development programs
targeted to address unmet medical needs, including both front and
back of the eye diseases. For more information on Kala, please
visit www.kalarx.com.
Investor Contacts: Jill
Steierjill.steier@kalarx.com781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024